Exciting updates in GI Cancers!
Dr. Axel Grothey from West Cancer Center shared groundbreaking insights at the Total Health Spring Oncology Review and Renew Conference. He highlighted major advancements in targeted therapies and precision medicine for GI cancers. Here are the key highlights:
- Gastro-Esophageal Junction (GEJ) Cancers: Dr. Grothey revealed a new biomarker, Claudin 18.2 (CLDN 18.2), as a potential target in GEJ cancers. Zolbetuximab, an antibody, was used in combination with mFOLFOX6 chemotherapy regimen in the SPOTLIGHT trial. Promisingly, the trial demonstrated improved progression-free survival (PFS) and overall survival (OS) in patients expressing CLDN 18.2. This discovery has the potential to transform GEJ cancer treatment.
- Pancreatic Cancer: Dr. Grothey discussed the NAPOLI 3 trial, which evaluated NALIRFOX (liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin) versus the standard Gem+NabP regimen for metastatic pancreatic ductal adenocarcinoma. NALIRFOX showed statistically significant benefits in overall survival (OS) and progression-free survival (PFS). It also exhibited a higher objective response rate (ORR). These findings indicate a potentially more effective treatment option for pancreatic cancer.
- Metastatic Colorectal Cancer: Results from the SUNLIGHT phase III study were presented, evaluating trifluridine/tipiracil in combination with bevacizumab as a third-line treatment for metastatic colorectal cancer. The combination therapy demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), response rate (RR), and disease control rate (DCR). This could potentially reshape the standard of care for treatment-refractory colorectal cancer.
Dr. Grothey’s insights shed light on the progress made in GI cancers, offering hope and new possibilities for patients. Stay tuned for more updates in the field!